Lumenis holmium and dual wavelength lasers enable precise, minimally invasive treatment for a wide variety of urologic conditions such as:

• Benign prostatic hyperplasia (BPH)
• Bladder, ureteral, urethral and kidney stones
• Bladder tumors
• Bladder neck incision
• Urethral strictures
• Urethral and ureteral tumors

Lumenis' commitment to laser technology and close collaboration with customers and endoscopic manufacturers has led to impressive innovations in urology. In fact, our achievements in the specialty include many "firsts:"

• First to support clinical research and use of the holmium laser for urinary lithotripsy and treatment of BPH
• First to receive U.S. Food & Drug Administration clearance for the surgical treatment of BPH with the holmium laser.
• First to develop multi-wavelength surgical lasers
• First and only company to develop the powerful 100 watt holmium laser
• First to develop a tissue morcellator for holmium laser prostatectomy
• First to partner and pioneer world class training centers for surgeons to learn holmium laser prostatectomy techniques

Today, the multipurpose VersaPulse PowerSuite holmium laser system is considered an essential and innovative surgical tool for urologists. The holmium technology in the VersaPulse PowerSuite systems has become a standard of care for treating urinary stone disease and BPH. With several upgradeable holmium and dual wavelength laser systems, the VersaPulse PowerSuite line provides both the power for today as well as tomorrow. With more than 20 delivery devices including a wide array of disposable and reusable fibers, Lumenis continues to demonstrate its long term commitment to serve urology customers with state-of-the-art products and support services.